Hospitalizations Fall In NY, But Not As Quickly As Other COVID Hotspots: Live Updates Summary: Hospitalizations fall in NY, but not as fast as other hotspots...
The Biden administration is exploring every option for increasing manufacturing of Johnson & Johnson’s Covid-19 vaccine, which is under regulatory review, and said on Feb. 5...
Johnson & Johnson’s Janssen Biotech submitted an application to the U.S. Food and Drug Administration for emergency use authorization (EUA) for a single-dose Covid-19 vaccine.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in...
Ocugen (OCGN) announced it had finalized its deal with India-based Bharat Biotech top commercialize COVAXIN COVID-19 vaccine already in use in India
AstraZeneca Jab Works Against Mutant COVID; JNJ Asks For US Approval: Live Updates Summary: AstraZeneca jab effective against COVID mutant JNJ asks US for regulatory approval...
J&J said its EUA will be based on topline efficacy and safety data from the nearly 44,000-patient Phase III ENSEMBLE trial
Johnson & Johnson’s Janssen unit has filed its single dose COVID-19 vaccine candidate with the FDA, asking for The post J&J asks FDA for emergency clearance...
Gilead’s COVID-19 drug Veklury (remdesivir) is helping the company through disruption caused by the pandemic and patent expiry The post Veklury rescues Gilead from COVID doldrums...
Stirred to action by the COVID-19 pandemic, vaccine stalwarts mobilize new formats, accelerate development, and scale up manufacturing. The post The Sleeping Giants of Vaccine Production...
Moderna is proposing filling vials with additional doses of the COVID-19 vaccine to increase supply as the company approaches the manufacturing of almost a million doses...
Pfizer Increased its 202 guidance as the US drug maker expects to generate $15 billion from the sale of its COVID-19 vaccine.
In the race to bring a coronavirus vaccine to market, Novavax was looking like a loser after delays in Phase 3 trials.
Diversifying a portfolio is often cited as a safe investing strategy, but it is also the game plan adopted by Sorrento Therapeutics (SRNE). This varied approach...
Johnson & Johnson said the company's single-dose vaccine was 66% effective in preventing Covid-19 in a large global trial against multiple variants, giving health officials another...
NVX-CoV2373 achieved 60% efficacy in a Phase IIb trial in South Africa, where that country’s escape variant of the virus (B.1.351, also known as 20H/501Y.V2) was...
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else...
Eli Lilly said new data showed that treatment with 2 of its antibody therapies lowered COVID-19-related hospitalizations & deaths in high-risk patients by 70%.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir's investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild...
Eli Lilly and Regeneron have reported results from new studies that show positive results in people at high risk of infection.
The COVID-19 vaccine rollout has fallen far short of President Trump's promises. President Biden says he can fix that. Can he?
Eli Lilly and Co. will move a new Covid-19 antibody therapy to human trials targeting a coronavirus variant that was first found in South Africa
Eli Lilly and Co.’s combination antibody drug helped reduce the risk of hospitalization and death in Covid-19 patients by 70%, the drugmaker said, citing early data...
Regeneron Pharmaceuticals announced positive initial data from the company's ongoing Phase III trial of the antibody cocktail, REGEN-COV, as a passive vaccine to prevent Covid-19 in people...
Merck is stopping development of the company's two Covid-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
Merck & Co. has decided to stop the development of its two COVID-19 vaccine candidates following “inferior” immune responses. Shares slipped about 1% in Monday’s morning...
With the Pfizer-BioNTech and Moderna Covid-19 vaccines authorized in the United States and being distributed and dosed, some of the attention is shifting to Johnson &...
Phase 3 Trial Showed Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents
The 72-year-old patient was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunity and immunoglobulin...
Agency veteran Dr Janet Woodcock is the new interim FDA commissioner appointed by president Joe Biden to replace The post Biden appoints veteran Woodcock as interim...